Back to PFE
Phase 3
Development Phase
1
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
Upcoming Catalysts
What are catalysts?Competitive Landscape
Drug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA2/16/2024
Velsipity
Velsipity is indicated for the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.
View on EMADrug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts